ASCO 2024 Study: Early Oliparib Monotherapy May Improve Therapy Duration and Survival Using ConcertAI Dataset

ConcertAI has unveiled a significant study, set to be presented at the 2024 ASCO Annual Meeting, showcasing the potential benefits of early olaparib monotherapy for patients with metastatic castration-resistant prostate cancer (mCRPC). This analysis, carried out in collaboration with Merck & Co., Inc., and AstraZeneca, suggests that early intervention with olaparib could enhance therapy duration and overall survival in mCRPC patients.

The study utilized ConcertAI's extensive real-world oncology dataset, which includes de-identified patient records. It specifically focused on patients with homologous recombination repair gene mutation (HRRm), often subjected to multiple lines of therapy before receiving olaparib. These patients, all diagnosed with mCRPC and aged 21 years or older, were treated with olaparib monotherapy after May 19, 2020, and prior to using abiraterone or enzalutamide. The dataset spans diagnoses from 1990 to 2023.

Key findings revealed that many mCRPC patients with HRRm are administered various treatments before olaparib, despite the use of novel hormonal agents (NHAs) prior to mCRPC diagnosis. The study summarized the frequency of progression from metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic CRPC (nmCRPC) to mCRPC, along with the treatment patterns observed prior to mCRPC.

Jeff Elton, PhD, CEO of ConcertAI, emphasized the study's implications, noting that real-world data can significantly inform treatment decisions and enhance patient outcomes. He stated, "By analyzing our vast dataset of de-identified patient records, we were able to provide compelling evidence that earlier treatment with olaparib can significantly extend the duration of therapy and overall survival for patients with metastatic castration-resistant prostate cancer. This reinforces our core mission of transforming data housed in electronic health records into actionable insights that directly benefit patient care."

The findings will be showcased during a poster session at the ASCO Annual Meeting on June 2, 2024, from 9:00 am to 12:00 pm, with the poster identified as #460. Attendees can also visit ConcertAI's booth, number 12045, throughout the event.

ConcertAI is renowned for its expertise in predictive and generative AI SaaS solutions, alongside its real-world data research capabilities. The company aims to accelerate patient outcomes through advanced AI technologies and comprehensive data analysis, partnering with leading biomedical innovators, healthcare providers, and medical societies. ConcertAI's solutions are widely deployed, serving 2,000 clinical providers globally and collaborating with 45 leading biopharmaceutical companies. With its headquarters in Cambridge, MA, ConcertAI also maintains offices in Frankfurt, London, Philadelphia, Raleigh-Durham, and Tokyo.